2 Matching Annotations
  1. Last 7 days
    1. Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma

      [Paper-level Aggregated] PMCID: PMC6173734

      Evidence Type(s): Oncogenic, Functional

      Justification: Oncogenic: The text mentions a pathogenic TP53 missense variant c.422G>A (p.Cys141Tyr), indicating that this variant is associated with tumorigenesis and is likely to contribute to cancer development. Functional: The presence of the pathogenic TP53 variant suggests that it may affect the function of the TP53 protein, which is critical for regulating the cell cycle and preventing tumor formation.

      Gene→Variant (gene-first): TP53(7157):c.422G>A TP53(7157):p.Cys141Tyr

      Genes: TP53(7157)

      Variants: c.422G>A p.Cys141Tyr

    2. Whole-genome sequencing of fresh-frozen tumour DNA (116x average depth) and matched germline DNA (43x average depth) revealed a t(12;15)(p13.2;q25.3) translocation, resulting in an ETV6-NTRK3 fusion (Fig. 1a). The result

      [Paragraph-level] PMCID: PMC6173734 Section: RESULTS PassageIndex: 2

      Evidence Type(s): Oncogenic

      Justification: Oncogenic: The passage describes a pathogenic TP53 missense variant c.422G>A (p.Cys141Tyr) in the context of tumor development, indicating its contribution to tumor progression through the loss of heterozygosity and clonal biallelic loss of TP53.

      Gene→Variant (gene-first): 7157:c.422G>A 7157:p.Cys141Tyr

      Genes: 7157

      Variants: c.422G>A p.Cys141Tyr